CSTB and neoplasm: These new findings indicated a similar tendency with our previous results on the cysteine–protease inhibitor, cystatin-B, that presented reduced levels in neoplastic islands from the invasive tumor front and also in the saliva of N+ OSCC patients compared with that in N0 OSCC patients (19).